• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

相似文献

1
Mouse models of epithelial ovarian cancer for preclinical studies.用于临床前研究的上皮性卵巢癌小鼠模型。
Zool Res. 2021 Mar 18;42(2):153-160. doi: 10.24272/j.issn.2095-8137.2020.382.
2
Preclinical models of epithelial ovarian cancer: practical considerations and challenges for a meaningful application.上皮性卵巢癌的临床前模型:实际考虑因素及有意义应用的挑战。
Cell Mol Life Sci. 2022 Jun 16;79(7):364. doi: 10.1007/s00018-022-04395-y.
3
Patient-Derived Xenograft Models of Epithelial Ovarian Cancer for Preclinical Studies.上皮性卵巢癌患者来源异种移植模型用于临床前研究。
Cancer Res Treat. 2017 Oct;49(4):915-926. doi: 10.4143/crt.2016.322. Epub 2017 Jan 4.
4
ABT-510 induces tumor cell apoptosis and inhibits ovarian tumor growth in an orthotopic, syngeneic model of epithelial ovarian cancer.在原位同基因上皮性卵巢癌模型中,ABT-510可诱导肿瘤细胞凋亡并抑制卵巢肿瘤生长。
Mol Cancer Ther. 2009 Jan;8(1):64-74. doi: 10.1158/1535-7163.MCT-08-0864.
5
Establishment of Patient-Derived Tumor Xenograft Models of Epithelial Ovarian Cancer for Preclinical Evaluation of Novel Therapeutics.建立用于新型疗法临床前评估的上皮性卵巢癌患者来源的肿瘤异种移植模型。
Clin Cancer Res. 2017 Mar 1;23(5):1263-1273. doi: 10.1158/1078-0432.CCR-16-1237. Epub 2016 Aug 29.
6
The latest animal models of ovarian cancer for novel drug discovery.用于新型药物发现的最新卵巢癌动物模型。
Expert Opin Drug Discov. 2018 Mar;13(3):249-257. doi: 10.1080/17460441.2018.1426567. Epub 2018 Jan 17.
7
Xenograft and transgenic mouse models of epithelial ovarian cancer and non-invasive imaging modalities to monitor ovarian tumor growth in situ: applications in evaluating novel therapeutic agents.上皮性卵巢癌的异种移植和转基因小鼠模型以及用于原位监测卵巢肿瘤生长的非侵入性成像方法:在评估新型治疗药物中的应用
Curr Protoc Pharmacol. 2009 Jun;Chapter 14:Unit14.12. doi: 10.1002/0471141755.ph1412s45.
8
LY75 Suppression in Mesenchymal Epithelial Ovarian Cancer Cells Generates a Stable Hybrid EOC Cellular Phenotype, Associated with Enhanced Tumor Initiation, Spreading and Resistance to Treatment in Orthotopic Xenograft Mouse Model.LY75 抑制在间充质上皮性卵巢癌细胞中产生稳定的杂交 EOC 细胞表型,与增强的肿瘤起始、扩散和对原位异种移植小鼠模型中治疗的抗性相关。
Int J Mol Sci. 2020 Jul 15;21(14):4992. doi: 10.3390/ijms21144992.
9
Suppression of epithelial ovarian cancer invasion into the omentum by 1α,25-dihydroxyvitamin D3 and its receptor.1α,25-二羟基维生素D3及其受体对上皮性卵巢癌向大网膜浸润的抑制作用
J Steroid Biochem Mol Biol. 2015 Apr;148:138-47. doi: 10.1016/j.jsbmb.2014.11.005. Epub 2014 Nov 6.
10
Lurbinectedin (PM01183), a new DNA minor groove binder, inhibits growth of orthotopic primary graft of cisplatin-resistant epithelial ovarian cancer.鲁比卡丁(PM01183),一种新型 DNA 小沟结合剂,抑制顺铂耐药上皮性卵巢癌原位原发移植瘤的生长。
Clin Cancer Res. 2012 Oct 1;18(19):5399-411. doi: 10.1158/1078-0432.CCR-12-1513. Epub 2012 Aug 15.

引用本文的文献

1
Patient-Derived Xenograft Models for Ovarian Cancer.卵巢癌患者来源异种移植模型。
Methods Mol Biol. 2024;2806:187-196. doi: 10.1007/978-1-0716-3858-3_13.
2
Bridging the Gap from Bench to Bedside: A Call for In Vivo Preclinical Models to Advance Endometrial Cancer and Cervical Cancer Immuno-oncology Research.从基础到临床:呼吁建立体内临床前模型以推进子宫内膜癌和宫颈癌免疫肿瘤学研究。
Clin Cancer Res. 2024 Jul 15;30(14):2905-2909. doi: 10.1158/1078-0432.CCR-23-2570.
3
Anticancer Effects of BRD4 Inhibitor in Epithelial Ovarian Cancer.BRD4抑制剂在上皮性卵巢癌中的抗癌作用
Cancers (Basel). 2024 Feb 27;16(5):959. doi: 10.3390/cancers16050959.
4
Nanoparticle-Encapsulated Epirubicin Efficacy in the Inhibition of Growth of Orthotopic Ovarian Patient-Derived Xenograft in Immunocompromised Mice.载药纳米粒阿霉素抑制免疫缺陷荷瘤鼠原位卵巢移植瘤生长的实验研究。
Int J Mol Sci. 2024 Jan 4;25(1):645. doi: 10.3390/ijms25010645.
5
CASC4/GOLM2 drives high grade serous carcinoma anoikis resistance through the recycling of EGFR.CASC4/GOLM2 通过循环利用 EGFR 驱动高级别浆液性卵巢癌的抗失巢凋亡。
Cancer Gene Ther. 2024 Feb;31(2):300-310. doi: 10.1038/s41417-023-00703-1. Epub 2023 Nov 29.
6
Uterine microbial communities and their potential role in the regulation of epithelium cell cycle and apoptosis in aged hens.子宫微生物群落及其在调控老龄母鸡上皮细胞周期和凋亡中的潜在作用。
Microbiome. 2023 Nov 11;11(1):251. doi: 10.1186/s40168-023-01707-7.
7
The MYBL2-CCL2 axis promotes tumor progression and resistance to anti-PD-1 therapy in ovarian cancer by inducing immunosuppressive macrophages.MYBL2-CCL2轴通过诱导免疫抑制性巨噬细胞促进卵巢癌的肿瘤进展及对抗PD-1治疗的抗性。
Cancer Cell Int. 2023 Oct 21;23(1):248. doi: 10.1186/s12935-023-03079-2.
8
Establishment of highly metastatic ovarian cancer model with omental tropism via selection.通过筛选建立具有网膜嗜性的高转移性卵巢癌模型。
iScience. 2023 Apr 23;26(5):106719. doi: 10.1016/j.isci.2023.106719. eCollection 2023 May 19.
9
Harnessing preclinical models for the interrogation of ovarian cancer.利用临床前模型探究卵巢癌。
J Exp Clin Cancer Res. 2022 Sep 16;41(1):277. doi: 10.1186/s13046-022-02486-z.
10
The Proteolytic Landscape of Ovarian Cancer: Applications in Nanomedicine.卵巢癌的蛋白水解全景:在纳米医学中的应用。
Int J Mol Sci. 2022 Sep 1;23(17):9981. doi: 10.3390/ijms23179981.

本文引用的文献

1
Cancer statistics, 2020.癌症统计数据,2020 年。
CA Cancer J Clin. 2020 Jan;70(1):7-30. doi: 10.3322/caac.21590. Epub 2020 Jan 8.
2
An autologous humanized patient-derived-xenograft platform to evaluate immunotherapy in ovarian cancer.一种用于评估卵巢癌免疫疗法的自体人源化患者来源异种移植平台。
Gynecol Oncol. 2020 Jan;156(1):222-232. doi: 10.1016/j.ygyno.2019.10.011. Epub 2019 Dec 7.
3
Studying cancer immunotherapy using patient-derived xenografts (PDXs) in humanized mice.用人源化小鼠中的患者来源异种移植物(PDXs)研究癌症免疫疗法。
Exp Mol Med. 2018 Aug 7;50(8):1-9. doi: 10.1038/s12276-018-0115-0.
4
Ovarian cancer statistics, 2018.卵巢癌统计数据,2018 年。
CA Cancer J Clin. 2018 Jul;68(4):284-296. doi: 10.3322/caac.21456. Epub 2018 May 29.
5
Patient-derived xenografts effectively capture responses to oncology therapy in a heterogeneous cohort of patients with solid tumors.患者来源异种移植物有效地捕获了对实体瘤异质性患者群体中肿瘤治疗的反应。
Ann Oncol. 2017 Oct 1;28(10):2595-2605. doi: 10.1093/annonc/mdx416.
6
Preclinical Models of Ovarian Cancer: Pathogenesis, Problems, and Implications for Prevention.卵巢癌的临床前模型:发病机制、问题及预防意义
Clin Obstet Gynecol. 2017 Dec;60(4):789-800. doi: 10.1097/GRF.0000000000000312.
7
High-grade serous carcinomas arise in the mouse oviduct via defects linked to the human disease.高级别浆液性癌通过与人类疾病相关的缺陷在小鼠输卵管中发生。
J Pathol. 2017 Sep;243(1):16-25. doi: 10.1002/path.4927. Epub 2017 Jul 25.
8
Patient-Derived Xenograft Models of Epithelial Ovarian Cancer for Preclinical Studies.上皮性卵巢癌患者来源异种移植模型用于临床前研究。
Cancer Res Treat. 2017 Oct;49(4):915-926. doi: 10.4143/crt.2016.322. Epub 2017 Jan 4.
9
BET Bromodomain Inhibition Promotes Anti-tumor Immunity by Suppressing PD-L1 Expression.BET结构域抑制通过抑制PD-L1表达促进抗肿瘤免疫。
Cell Rep. 2016 Sep 13;16(11):2829-2837. doi: 10.1016/j.celrep.2016.08.032.
10
In vivo anti-tumor activity of the PARP inhibitor niraparib in homologous recombination deficient and proficient ovarian carcinoma.聚(ADP-核糖)聚合酶(PARP)抑制剂尼拉帕利在同源重组缺陷型和同源重组 proficient 型卵巢癌中的体内抗肿瘤活性 。 注:这里“proficient”原文有误,可能是“proficient”,正确的可能是“proficient homologous recombination”即“同源重组 proficient 型” ,但按照要求未做修改直接翻译了。 正常应该是“同源重组缺陷型和同源重组功能正常型” 。
Gynecol Oncol. 2016 Nov;143(2):379-388. doi: 10.1016/j.ygyno.2016.08.328. Epub 2016 Sep 8.

用于临床前研究的上皮性卵巢癌小鼠模型。

Mouse models of epithelial ovarian cancer for preclinical studies.

机构信息

Immunology, Microenvironment & Metastasis Program, The Wistar Institute, Philadelphia, PA 19104, USA.

Immunology, Microenvironment & Metastasis Program, The Wistar Institute, Philadelphia, PA 19104, USA. E-mail:

出版信息

Zool Res. 2021 Mar 18;42(2):153-160. doi: 10.24272/j.issn.2095-8137.2020.382.

DOI:10.24272/j.issn.2095-8137.2020.382
PMID:33527800
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC7995272/
Abstract

Epithelial ovarian cancer (EOC) is the leading cause of gynecological cancer-related mortality in the developed world. EOC is a heterogeneous disease represented by several histological and molecular subtypes. Therefore, exploration of relevant preclinical animal models that consider the heterogenic nature of EOC is of great importance for the development of novel therapeutic strategies that can be translated clinically to combat this devastating disease. In this review, we discuss recent progress in the development of preclinical mouse models for EOC study as well as their advantages and limitations.

摘要

上皮性卵巢癌 (EOC) 是发达国家妇科癌症相关死亡的主要原因。EOC 是一种异质性疾病,由几种组织学和分子亚型代表。因此,探索考虑 EOC 异质性的相关临床前动物模型对于开发新的治疗策略以对抗这种毁灭性疾病具有重要意义。在本文中,我们讨论了用于 EOC 研究的临床前小鼠模型的最新进展及其优缺点。